Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT00020670 · Dana-Farber Cancer Institute · EARLY_PHASE1 · terminated · last registry update 2017-06-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-06-08Phase 3 first posted: Kyowa Kirin Co., Ltd., Bardoxolone methyl + Placebo (NCT03550443)
- 2018-05-07Results posted on the registry: Sanofi, Alirocumab + Placebo (NCT02584504)
- 2018-04-02Results posted on the registry: VA Office of Research and Development, anakinra + actos (NCT02278562)
- 2018-03-02Phase 3 first posted: Wayne State University, Metformin + Pioglitazone (NCT03452267)
- 2018-01-26Phase 3 first posted: Ferring Pharmaceuticals, Budesonide (6 mg) + Budesonide (9 mg) (NCT03412682)
- 2018-01-19Results posted on the registry: Bausch Health Americas, Inc., Balsalazide Disodium (NCT00486031)
- 2017-12-12Results posted on the registry: National Jewish Health, Mesalamine + Placebo (NCT01088243)
- 2017-09-14Phase 3 first posted: Shire, 25 mg Ontamalimab + 75 mg Ontamalimab (NCT03283085)
- 2017-07-27Phase 3 first posted: Minoryx Therapeutics, S.L., Leriglitazone + Placebo (NCT03231878)
- 2017-03-01Phase 3 first posted: Biogen, Bardoxolone methyl (NCT03068130)
- 2017-01-12Phase 3 first posted: Biogen, Placebo Oral Capsule + Bardoxolone Methyl (NCT03019185)
- 2016-11-23Results posted on the registry: Eli Lilly and Company, Glimepiride + Metformin (NCT02072096)
- 2016-10-28Results posted on the registry: Yale University, pioglitazone + placebo (NCT00091949)
- 2016-10-12Phase 3 first posted: Jawaharlal Institute of Postgraduate Medical Education & Research, Methotrexate + Leflunomide (NCT02930343)
- 2016-09-22Phase 3 first posted: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Mercaptopurine (Purinethol) + Placebo (NCT02910245)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision